Categories: Health

Bavarian Nordic Transactions in Connection with Share Buy-Back Program

COPENHAGEN, Denmark, June 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from June 2, 2026 to July 10, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.

Since initiation of the program, the following transactions have been made by Nordea on behalf of Bavarian Nordic:

  Number of shares Average purchase price, DKK Transaction value, DKK
June 2, 2026  31,294 183.45  5,740,887
June 3, 2026  18,527 180.55  3,344,996
June 4, 2026  348 179.97  62,631
Accumulated under the program 50,169 182.35 9,148,515

The details for each transaction made under the share repurchase program are published on bavarian-nordic.com.

Following these transactions, Bavarian Nordic holds a total of 2,788,153 treasury shares, corresponding to 3.52% of the Company’s share capital.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Europe: Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel. +45 33 26 83 83
US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600

Contact media:
Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com, Tel: +45 53 88 06 03

Company Announcement no. 27 / 2026

GlobeNews Wire

Recent Posts

Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

June 26, 2026 16:05 ET  | Source: Universe Pharmaceuticals INC. Ji'an, Jiangxi, China, June 26,…

7 hours ago

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000, Russell 1000, Russell 2500 and Russell Midcap

June 26, 2026 16:01 ET  | Source: Ascendis Pharma COPENHAGEN, Denmark, June 26, 2026 (GLOBE…

7 hours ago

AiraBreeze Announces Entry into the Portable Cooling Products Industry with Introduction of Its First Consumer Cooling Solution

London, UK, June 28, 2026 (GLOBE NEWSWIRE) -- AiraBreeze today announced its entry into the…

8 hours ago

JellyFil Announces Entry into the Men’s Wellness Supplement Category with First Product Launch

LARGO, FL, June 28, 2026 (GLOBE NEWSWIRE) -- JellyFil, a company established in 2026, today…

8 hours ago

AirZuma Portable AC Announces Entry into the Portable Cooling Products Industry

New York City, NY, June 28, 2026 (GLOBE NEWSWIRE) -- AirZuma Portable AC today announced…

8 hours ago